Enlivex Therapeutics Ltd. (ENLV.TA)
Enlivex Therapeutics Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ness Ziona, IL. The stock last traded at $269.70, up 0.00% on the session, giving a market capitalisation of $65.5M. Its beta of 1.68 implies it has historically moved more than the broad market.
Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company specializing in immunotherapy through macrophage reprogramming. The company's primary therapeutic candidate, Allocetra, is a cell-based treatment currently in a Phase II clinical trial for organ dysfunction and failure linked to sepsis. Allocetra is also being investigated in preclinical studies for its application against solid tumors. Furthermore, Enlivex has partnered with BeiGene to evaluate Allocetra's safety and efficacy when administered alongside tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for advanced solid tumor patients. The company's headquarters are located in Ness Ziona, Israel.
Enlivex Therapeutics Ltd. is most often compared with the following Healthcare names: